jetcityimage/iStock Editorial via Getty Images Eli Lilly ( LLY ) on Thursday said it will seek a label expansion for its newly approved weight loss pill, Foundayo, in Q2 after the once-daily therapy succeeded in a Phase 3 trial for patients with type 2 diabetes. Citing topline data, the Indiana-based drugmaker said that its Phase 3 ACHIEVE-4 trial, designed to evaluate Foundayo against a long-acti...
jetcityimage/iStock Editorial via Getty Images Eli Lilly ( LLY ) on Thursday said it will seek a label expansion for its newly approved weight loss pill, Foundayo, in Q2 after the once-daily therapy succeeded in a Phase 3 trial for patients with type 2 diabetes. Citing topline data, the Indiana-based drugmaker said that its Phase 3 ACHIEVE-4 trial, designed to evaluate Foundayo against a long-acting form of insulin called insulin glargine in adults with type 2 diabetes, met the primary endpoint. The global trial for more than 2,700 adults reached its primary endpoint, as Foundayo was found to be non-inferior to insulin glargine in the risk of stroke, heart attacks, and other major adverse cardiovascular events, according to the company. In the study, Foundayo, also known as orforglipron, was associated with a 16% and 57% lower risk for major adverse cardiovascular events and risk of all-cause death compared to insulin glargine, respectively. However, during the 52-week minimum treatment period, nearly 11% of patients on Foundayo dropped out of the trial due to adverse events, despite the safety and tolerability data for the drug being roughly in line with its past studies. The open-label trial enrolled adults with type 2 diabetes and obesity or overweight who are at an increased risk for cardiovascular events. Eli Lilly ( LLY ) intends to seek a label expansion for Foundayo for type 2 diabetes by the end of Q2 under the FDA Commissioner's National Priority Review Voucher program, which accelerates the review of products developed by companies aligned with national priorities. More on Eli Lilly Even After Shedding Some Weight, Eli Lilly and Company Isn't Prime For An Upgrade Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides Lilly required by FDA to run post-marketing studies on obesity pill
U.S. Bancorp ( USB ) stock drifted up 1.1% in Thursday premarket trading after the Minneapolis-based bank posted Q1 earnings that beat the Wall Street consensus and reaffirmed its full-year guidance. The bank highlighted its robust loan growth and improved payments performance. The bank still sees FY2026 net revenue growth of 4%-6% and positive operating leverage of 200+ bps. For Q2, the company e...
U.S. Bancorp ( USB ) stock drifted up 1.1% in Thursday premarket trading after the Minneapolis-based bank posted Q1 earnings that beat the Wall Street consensus and reaffirmed its full-year guidance. The bank highlighted its robust loan growth and improved payments performance. The bank still sees FY2026 net revenue growth of 4%-6% and positive operating leverage of 200+ bps. For Q2, the company expects net interest income (“FTE”) to rise 6%-7% from Q2 2025's $4.08B, and total fee revenue to increase 6%-7% Y/Y from Q2 2025's $2.98B. That implies Q2 net interest income of $4.32B-$4.37B vs. the Visible Alpha consensus of $4.38B and total fee revenue of $3.16B-$3.19B. Q2 total noninterest expense is projected to grow 3%-4% from 2025's $4.18B, implying $4.31B-$4.35B vs. the Visible Alpha consensus of $4.37B. Q1 GAAP EPS of $1.18, vs. the average analyst estimate of $1.14, declined from $1.26 in Q4 2025 and rose from $1.03 in Q1 2025. Q1 total revenue of $7.29B, in line with the $7.29B consensus, dropped from $7.37B in the previous quarter and increased from $6.96B in the year-ago period. "Net interest income growth of 4.1% compared with the prior year was supported by robust loan growth in priority areas, including commercial and credit card, and record consumer deposits," said CEO Gunjan Kedia. "Fee revenue increased 6.9% year-over-year, reflecting improved payments performance and continued momentum across capital markets and investment services businesses. Credit quality and capital levels remain healthy and strong." Provision for credit losses of $576M vs. $577M in the prior quarter and $537M a year ago. Its net charge-off ratio, excluding notable items, was 0.56%, compared with 0.54% in Q4 and 0.59% in last year’s Q1. Net interest income on a taxable equivalent basis of $4.29B, matching the Visible Alpha estimate, fell from $4.31B in the previous quarter and increased from $4.12B in the year-ago period. Net interest margin (taxable equivalent) was 2.77% vs. 2.77% i...
Goldman Sachs To Use Options Strategy For Planned Bitcoin Income ETF Authored by Nate Kostar via CoinTelegraph.com, Goldman Sachs has filed with the US Securities and Exchange Commission (SEC) to launch a Bitcoin-linked exchange-traded fund designed to generate income while limiting exposure to the cryptocurrency’s volatility, according to a preliminary prospectus dated April 14. The proposed Gold...
Goldman Sachs To Use Options Strategy For Planned Bitcoin Income ETF Authored by Nate Kostar via CoinTelegraph.com, Goldman Sachs has filed with the US Securities and Exchange Commission (SEC) to launch a Bitcoin-linked exchange-traded fund designed to generate income while limiting exposure to the cryptocurrency’s volatility, according to a preliminary prospectus dated April 14. The proposed Goldman Sachs Bitcoin Premium Income ETF would aim to deliver current income alongside capital appreciation by investing primarily in spot Bitcoin exchange-traded products (ETPs) and related options, rather than holding Bitcoin directly. The fund would generate yield by selling call options on Bitcoin-linked ETPs, a strategy that can produce premium income but may cap upside in rising markets. According to the filing, the actively managed fund would maintain at least 80% exposure to Bitcoin-linked assets and could allocate as much as 25% of its holdings through a Cayman Islands subsidiary, a structure commonly used to gain commodities exposure under the US Investment Company Act. The fund expects to vary its options “overwrite” strategy — that is, selling call options against its holdings — between roughly 40% and 100% of its Bitcoin exposure depending on market conditions, and may distribute a significant portion of returns as income or return of capital. It would gain exposure through a mix of spot Bitcoin ETPs and derivatives, combining direct holdings with options-based positions. The strategy may perform better in flat or moderately rising markets but could underperform during strong rallies as upside is capped. Eric Balchunas, ETF analyst at Bloomberg, described the product as “Boomer Candy” in a post on X , suggesting the structure may appeal to investors seeking income and lower volatility over full upside exposure. Source: Eric Balchunas Separately, Goldman Chair and CEO David Solomon told analysts on Monday that the company last week closed on its acquisition of Innov...
Micron Technology (NASDAQ: MU) and Palantir Technologies (NASDAQ: PLTR) have been among the hottest artificial intelligence (AI) stocks on the market over the past couple of years. While Micron stock has shot up by a remarkable 272%, Palantir has posted an even bigger gain of 527%. However, both companies have been under pressure of late. Palantir stock is down 20% so far in 2026, and Micron has b...
Micron Technology (NASDAQ: MU) and Palantir Technologies (NASDAQ: PLTR) have been among the hottest artificial intelligence (AI) stocks on the market over the past couple of years. While Micron stock has shot up by a remarkable 272%, Palantir has posted an even bigger gain of 527%. However, both companies have been under pressure of late. Palantir stock is down 20% so far in 2026, and Micron has been volatile over the past month amid concerns about the sustainability of AI-fueled memory demand following a potential technological breakthrough from Alphabet that could reduce the need for memory chips in data centers. Moreover, Palantir continues to trade at a very expensive 225 times trailing earnings and 108 times forward earnings, even after its recent pullback. On the other hand, analysts are expecting that Micron's earnings will grow significantly in its next couple of years, but then slide in the year after that. These factors could weigh on their stock prices going forward. Meanwhile, Advanced Micro Devices (NASDAQ: AMD) has been gradually gaining ground in the AI data center space, and it won't be surprising to see it outperforming both Palantir and Micron over the next three years. Continue reading
航运分析机构劳氏情报（Lloyd’s List Intelligence）数据显示，近几日穿越霍尔木兹海峡的大部分货船，均采用了伊朗为控制该水域而划定的航线。 这家航运数据公司称，自4月13日以来其追踪到的27艘穿越海峡的大型商船中，约有15艘使用了伊朗强制要求的、紧贴伊朗海岸线的航线。伊朗政府已于4月初通知船东使用该航线，并表示计划收取过境费。数据显示，暂无船只使用主流的非伊朗航线。其余船只则往...
航运分析机构劳氏情报（Lloyd’s List Intelligence）数据显示，近几日穿越霍尔木兹海峡的大部分货船，均采用了伊朗为控制该水域而划定的航线。 这家航运数据公司称，自4月13日以来其追踪到的27艘穿越海峡的大型商船中，约有15艘使用了伊朗强制要求的、紧贴伊朗海岸线的航线。伊朗政府已于4月初通知船东使用该航线，并表示计划收取过境费。数据显示，暂无船只使用主流的非伊朗航线。其余船只则往返于紧邻海峡的伊朗阿巴斯港。 数据同时显示，4月以来穿越海峡的船只中，81%通过船东归属、船旗、挂靠伊朗港口或其他关联方式与伊朗存在联系。上述统计仅涵盖载重吨位超1万吨的大型货船过境情况。 美军于4月13日对伊朗港口实施封锁。美国中央司令部称，目前尚无船只成功突破封锁，已有10艘船只被勒令返航。 2月底美以对伊朗发起轰炸行动后不久，伊朗即宣布关闭霍尔木兹海峡，导致该海峡超90%的过境航运中断。战前，每日通常有约130艘船只通过该海峡。 航运数据显示，一艘受美国制裁的名为RHN的原油油轮于周三驶入波斯湾。该船因与伊朗开展业务被美国财政部列入制裁名单。公开航运数据显示，该船周四在伊朗海岸附近航行，未显示目的地。劳氏情报资深风险与合规分析师、船舶追踪专家布里奇特·迪亚昆表示：“航运仍在每日进行，其中大部分与伊朗相关。” 责任编辑：刘明亮
Old Vic theatre, London Director Clint Dyer brings a fresh political focus to Ken Kesey’s story of disempowerment but the relentless misogyny of the text feels retrograde When Randle P McMurphy is thrust into an American psychiatric hospital in the early 1960s, the torpid air begins to crackle. As the anarchic McMurphy, Aaron Pierre gives a storming performance but although Clint Dyer’s stirring t...
Old Vic theatre, London Director Clint Dyer brings a fresh political focus to Ken Kesey’s story of disempowerment but the relentless misogyny of the text feels retrograde When Randle P McMurphy is thrust into an American psychiatric hospital in the early 1960s, the torpid air begins to crackle. As the anarchic McMurphy, Aaron Pierre gives a storming performance but although Clint Dyer’s stirring take on Ken Kesey’s 1962 novel boldly reframes the story, the text can’t support his ideas. McMurphy immediately locks horns with authoritarian Nurse Ratched (Olivia Williams). He pivots and provokes, urging fellow patients to resist, play and party. Pierre roams the space with a pumped-up strut or an incongruous dainty scamper. He gives good fraternal hugs, but there’s a frantic vulnerability beneath the booming laugh. Continue reading...
"The Pulse With Francine Lacqua" is all about conversations with high profile guests in the beating heart of global business, economics, finance and politics. Based in London, we go wherever the story is, bringing you exclusive interviews and market-moving scoops. Today's guests: Claudia Panseri, France CIO at UBS Wealth Management; Carmine Di Noia, Director for Financial and Enterprise Affairs at...
"The Pulse With Francine Lacqua" is all about conversations with high profile guests in the beating heart of global business, economics, finance and politics. Based in London, we go wherever the story is, bringing you exclusive interviews and market-moving scoops. Today's guests: Claudia Panseri, France CIO at UBS Wealth Management; Carmine Di Noia, Director for Financial and Enterprise Affairs at the OECD & Lydia Rainforth, Head of European Energy & Energy Transition Research at Barclays. (Source: Bloomberg)
Chesky_W/iStock via Getty Images Vertical Aerospace ( EVTL ) rose in premarket trading as it announced the completion of its first two-way piloted transition flight in a full-scale tiltrotor eVTOL. This was also the first time such a flight was completed under civil aviation Design Organisation Approval regulatory oversight, according to the company. The flight validates the technology that will d...
Chesky_W/iStock via Getty Images Vertical Aerospace ( EVTL ) rose in premarket trading as it announced the completion of its first two-way piloted transition flight in a full-scale tiltrotor eVTOL. This was also the first time such a flight was completed under civil aviation Design Organisation Approval regulatory oversight, according to the company. The flight validates the technology that will drive Vertical’s commercial Valo air taxi, the company added. “This is now the most significant technical milestone in our history. Full piloted transition is the most critical and complex challenge in eVTOL development, and we’ve achieved it under more rigorous regulatory oversight than anyone in the category. We’re not just participating in this industry - we are helping to define it. Our focus now is on executing our roadmap and bringing certified electric flight into commercial service,” CEO Stuart Simpson said. With all phases of flight now proven, Vertical ( EVTL ) will proceed to the next stage of certification testing, including critical design review, and building seven pre-production Valo aircraft in the UK for compliance and verification testing. Vertical is targeting certification of Valo in 2028, followed shortly by entry into service. Vertical’s shares were up around 8% premarket on Thursday, as were other eVTOL-associated stocks such as Joby Aviation ( JOBY ) +2.5% , Archer Aviation ( ACHR ) +3% and EHang Holdings ( EH ) +2.8% . Source: Press Release More on Vertical Aerospace Vertical Aerospace: Liquidity Crisis Deepens As Transition Delay Triggers Dilution Spiral Vertical Aerospace Ltd. 2025 Q4 - Results - Earnings Call Presentation Vertical Aerospace Ltd. (EVTL) Q4 2025 Earnings Call Transcript Vertical Aerospace achieves major milestone with eVTOL flight development Vertical Aerospace confirms $850M funding to finance eVTOL certification, commercialization
DigitalVision/iStock via Getty Images Aligos Therapeutics ( ALGS ) entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China. Under the terms of the agreement, Aligos ( ALGS ) will receive an upfront milestone of $25M with the potential to earn up to $420M in add...
DigitalVision/iStock via Getty Images Aligos Therapeutics ( ALGS ) entered into an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus infection across Greater China. Under the terms of the agreement, Aligos ( ALGS ) will receive an upfront milestone of $25M with the potential to earn up to $420M in additional development, regulatory, and commercial milestone payments, along with tiered high single-digit royalties on net sales in the licensed territories. Amoytop Biotech will assume responsibility for development and commercialization in Greater China, while Aligos ( ALGS ) retains rights to the drug in other major markets, including the U.S., Europe, Japan, and South Korea. The collaboration is strategically significant given the large hepatitis B patient population in Greater China and allows Aligos to reduce development costs while extending its financial runway. More on Aligos Therapeutics Seeking Alpha’s Quant Rating on Aligos Therapeutics Historical earnings data for Aligos Therapeutics Financial information for Aligos Therapeutics
Jim Cramer made a pointed call this week: in the context of Meta Platforms (NASDAQ:META) partnering with Broadcom (NASDAQ:AVGO) to produce tens of millions of custom AI chips, Cramer said “But Broadcom is the one that I think you need to focus on.” I agree, and here’s why: Why Broadcom, and Why Now After a ... Cramer says Broadcom is the real play in Meta’s chip partnership
Jim Cramer made a pointed call this week: in the context of Meta Platforms (NASDAQ:META) partnering with Broadcom (NASDAQ:AVGO) to produce tens of millions of custom AI chips, Cramer said “But Broadcom is the one that I think you need to focus on.” I agree, and here’s why: Why Broadcom, and Why Now After a ... Cramer says Broadcom is the real play in Meta’s chip partnership